TORONTO—Health Canada, the federal agency that regulates the country’s healthcare delivery, is recalling lots of a drug used to treat iron and aluminum toxicity in dialysis patients due to the possibility of tiny particles forming after the drug is prepared for intravenous administration.
Health Canada said it is working with manufacturer Hospira Healthcare Corp. in recalling certain lots of Desferrioxamine Mesilate for Injection, which treats acute or chronic iron toxicity and chronic aluminum overload in dialysis patients with end-stage renal disease.
The formation of particles in the affected lots might produce cloudiness after preparation. These particles can block small blood vessels after injection.
The following are being recalled: Lot U072231AA in a 500-mg format and Lot U102237AA in a 2-g format. The lot number is on the label of the carton as well as on the vial.
Canada’s federal agency said that the name Mayne Pharma Canada Inc. appears on the labels and cartons because Hospira acquired the product from them.
For more information, contact Health Canada's public inquiries line at (613)957-2991 or toll-free at (866) 225-0709.
